Clinical trials · Illinois
Acute Lymphoblastic Leukemia clinical trials in Illinois
We’re tracking 31 recruiting acute lymphoblastic leukemia studies with a site in Illinois — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 alone or with other drugs for leukemia
This study tests a new medicine called AZD4512, given alone or with other cancer drugs, for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not improved after treatment. The goal is to see if it can help control the disease.
Chicago, IllinoisAges 12 years+ - NCT06785324Recruiting
Nutrition and exercise for adults with ALL in the hospital
This trial tests whether adding a structured diet and exercise program during your hospital stay for newly diagnosed ALL can help your recovery. You must have a specific type of ALL and be receiving a certain chemotherapy regimen.
Chicago, IllinoisAges 18–50 - NCT06918431RecruitingPhase 2
Erwinia asparaginase with chemo for new ALL or LBL
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
Chicago, IllinoisAges 18–54 - NCT04150497RecruitingPhase 1/Phase 2
Testing a new cell therapy for CD22-positive leukemia
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
Chicago, IllinoisAges 15–50 - NCT06446661Recruiting
Text message reminders for ALL oral chemo
This study tests whether text message reminders can help patients stick to their daily oral chemotherapy schedule during the maintenance phase of ALL treatment. Participants receive friendly text reminders and can ask questions, aiming to make managing treatment easier.
Chicago, IllinoisAges 15 years+ - NCT06376162RecruitingPhase 1
Ziftomenib with chemotherapy for children with relapsed leukemia
This trial tests whether adding a new drug called ziftomenib to standard chemotherapy can help children whose leukemia has come back or not responded to treatment. It is for children with certain genetic changes in their leukemia cells.
Chicago, IllinoisAges birth–21 years - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Chicago, IllinoisAges Up to 12 months - NCT06207123RecruitingPhase 1/Phase 2
New drug combo for T-cell leukemia or lymphoma
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Chicago, IllinoisAges birth–18 years - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Chicago, IllinoisAges 12 years+ - NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Chicago, IllinoisAges 1 year–46 years - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+ - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Chicago, IllinoisAges 6–39 - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Alton, IllinoisAges 40–75 - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
Chicago, IllinoisAges 1–40 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Park Ridge, IllinoisAges Up to 22 years - NCT04747912RecruitingPhase 2
Chemotherapy-free early treatment for Ph+ ALL using inotuzumab
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
Chicago, IllinoisAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Peoria, IllinoisAges 1–30 - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Chicago, IllinoisAges 4 weeks+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Winfield, IllinoisAges 12 months–25 years - NCT03932903Recruiting
Phone coaching to help teens stay on leukemia medicine
This trial tests a mobile (phone) health program to help adolescents and young adults with leukemia take their oral chemotherapy medicine consistently. It may help if staying on daily pills is hard during the maintenance phase of treatment.
Chicago, IllinoisAges 14 years+ - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Alton, IllinoisAges 18 years+ - NCT03571321RecruitingPhase 1
Ruxolitinib plus chemotherapy for Ph-like B-ALL
This early-phase study tests whether adding ruxolitinib (a targeted medicine) to standard chemotherapy improves outcomes in adolescents and young adults with newly diagnosed Ph-like B-precursor acute lymphoblastic leukemia (ALL). It targets specific genetic features (“JAK-targetable signature”) thought to make the leukemia more responsive to JAK-blocking treatment.
Chicago, IllinoisAges 18–39 - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Alton, IllinoisAges 18–39
Acute Lymphoblastic Leukemia trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting acute lymphoblastic leukemia studies listed above.
- University of Chicago Comprehensive Cancer Center · 10 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 9 studies
- University of Illinois · 7 studies
- Southern Illinois University School of Medicine · 6 studies
- Children's Hospital of Illinois at OSF Saint Francis Medical Center · 5 studies
- Loyola University Medical Center · 5 studies
- Advocate Children's Hospital - Park Ridge · 4 studies
- Advocate Children's Hospital Oak Lawn · 4 studies
What taking part in a acute lymphoblastic leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Acute Lymphoblastic Leukemia trials in other states
Common questions
- Are there acute lymphoblastic leukemia clinical trials in Illinois?
- Yes. We're currently tracking 31 recruiting acute lymphoblastic leukemia studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute lymphoblastic leukemia study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute lymphoblastic leukemia studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.